While many other mechanisms for primary resistance to EGFR-TKI or ErbB targeting monoclonal antibodies are plausible (e.g. expression of multidrug resistance channels, particular metabolizing enzymes, inactivation of tumour suppressors such as PTEN), none of them has been experimentally validated or confirmed in preclinical models or in clinical samples. Here, EGFR is linked to neoplasm.